FDA movement of peptides toward 503A bulks listing advanced despite internal scientific objections citing absent human ...

Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care. Patients receiving injectable glucagon-like peptide-1 receptor agonist (GLP-1 ...

Sophy Levine, PharmD, discusses how an integrated health system specialty pharmacy may help lower 1-year GLP-1 discontinuation.

Safety-net claims emphasize disproportionate Medicaid and uncompensated care borne by 340B hospitals, whereas other analyses ...

AJMC: The release notes that sustaining progress "may depend on access to early cancer detection, timely diagnosis, and state-of-the-art treatment." Beyond smoking reduction, which of those access ...

CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...

Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the ...

Adaolisa Anaka, PharmD, BCACP, AAHIVP, discusses a pharmacist-led model that targets access barriers to GLP-1 obesity therapy. Glucagon-like peptide-1 (GLP-1) receptor agonists have become a key ...

Prior authorization remains the dominant friction point, with nearly universal reporting of delays that widen the gap between ...

A propensity score–matched analysis (342 pairs) found lower REM sleep percentage in melatonin users versus nonusers (16.7% vs 19.0%; Hedges g −0.22; FDR P=.003). Multiple PSG measures, including total ...

Community oncology practices face steep structural barriers to clinical trial enrollment, and pragmatic trial design that ...

In part 2, David Johnson, MD, MPH, discusses how real-time data can sustain gold carding, ease prior authorization burden, ...